ArticleBMC infectious diseases2011
Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases.
Article in BMC infectious diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 51 citations in OpenAlex.
- Invasive aspergillosis in autoimmune inflammatory rheumatic diseases: epidemiology, risk factors, diagnosis, management and challenges.Annals of medicine · 2026Review
- Prognostic impact of rheumatoid arthritis on respiratory-related mortality in non-tuberculous mycobacterial pulmonary disease.RMD open · 2026Article
- Clinical implications of traction bronchiectasis in IPF and fibrotic RA-ILD - a retrospective single-center cohort study.Respiratory research · 2026Article
- Causal relationship between rheumatoid arthritis and bronchiectasis: a bidirectional mendelian randomization study.Arthritis research & therapy · 2024Article
- The causal relationship between rheumatoid arthritis and bronchiectasis: a bidirectional Mendelian randomization study.Frontiers in medicine · 2024Article
- Systemic sclerosis and risk of bronchiectasis: a nationwide longitudinal cohort study.Arthritis research & therapy · 2023Article
- Ultrasonographic Presentation and Anatomic Distribution of Lung Involvement in Patients with Rheumatoid Arthritis.Diagnostics (Basel, Switzerland) · 2023Article
- Pathogenesis of Extraarticular Manifestations in Rheumatoid Arthritis-A Comprehensive Review.Biomedicines · 2023Review
- Bronchiectasis is as crucial as interstitial lung disease in the severe pneumonia that occurs during treatment with biologic DMARDs in rheumatoid arthritis: a retrospective cohort study in a single facility.Rheumatology international · 2022Article
- Airway Disease in Rheumatoid Arthritis.Annals of the American Thoracic Society · 2022Review
- Review
- Clinical outcomes and prognostic factors of bronchiectasis rheumatoid overlap syndrome: A multi-institution cohort study.Frontiers in medicine · 2022Article
- Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Identification of Subclinical Lung Involvement in ACPA-Positive Subjects through Functional Assessment and Serum Biomarkers.International journal of molecular sciences · 2020Article
- Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis.Internal medicine (Tokyo, Japan) · 2019Article
- Lung Infections in Systemic Rheumatic Disease: Focus on Opportunistic Infections.International journal of molecular sciences · 2017Review
- Lung disease in rheumatoid arthritis.Rheumatic diseases clinics of North America · 2015Review
- Prevalence and risk factors for chronic co-infection in pulmonary Mycobacterium avium complex disease.BMJ open respiratory research · 2014Article
- The risk factors for nosocomial infection in chinese patients with active rheumatoid arthritis in shanghai.ISRN rheumatology · 2012Article
- The immune response and its therapeutic modulation in bronchiectasis.Pulmonary medicine · 2012Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBronchiectasis is frequently associated (up to 30%) with chronic inflammatory rheumatic diseases and leads to lower respiratory tract infections. Data are lacking on the risk of lower respiratory tract infections in patients treated with biologic agents.
methodsMonocenter, retrospective systematic study of all patients with a chronic inflammatory rheumatic disease and concomitant bronchiectasis, seen between 2000 and 2009. Univariate and multivariate analyses were performed to evidence predictive factors of the number of infectious respiratory events.
results47 patients were included (mean age 64.1±9.1 years, 33 (70.2%) women), with a mean follow-up per patient of 4.3±3.1 years. Rheumatoid arthritis was the main rheumatic disease (90.1%). The mean number of infectious events was 0.8±1.0 event per patient-year. The factors predicting infections were the type of treatment (biologic vs. non biologic disease-modifying treatments), with an odds ratio of 8.7 (95% confidence interval: 1.7-43.4) and sputum colonization by any bacteria (odds ratio 7.4, 2.0-26.8). In multivariate analysis, both factors were independently predictive of infections.
conclusionLower respiratory tract infectious events are frequent among patients receiving biologics for chronic inflammatory rheumatic disease associated with bronchiectasis. Biologic treatment and pre-existing sputum colonization are independent risk factors of infection occurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.